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Background: Esophagectomy is one of the most invasive surgical treatments for digestive tract cancer, and the
blood levels of inflammatory cytokines such as interleukin-1, interleukin-6, and interleukin-8 are increased for several
hours after surgery or in patients experiencing postoperative complications. CXCR2, an interleukin-8 receptor, is
reportedly expressed in several carcinomas, and interleukin-8 signaling promotes cancer cell proliferation. The
impact of postoperative complications following esophagectomy on long-term survival is controversial. In this
study, we demonstrate the significance of CXCR2 expression and validate the effects of CXCR2 expression and
postoperative complications on long-term prognosis of esophageal squamous cell carcinoma using resected
specimens.
Methods: Eighty-two specimens were sectioned from archived, paraffin-embedded tumor tissues obtained from
patients with esophageal squamous cell carcinoma who underwent esophagectomy and extended
lymphadenectomy for complete resection of cancer in our institute between 1997 and 2002.
Immunohistochemistry was performed using a polyclonal antibody to CXCR2, and the correlation of stainability
with clinicopathological factors and long-term survival was examined.
Results: CXCR2 was expressed in 33 of 82 (40.2 %) specimens. In the CXCR2-positive group, the recurrence-free
survival and overall survival rates of patients who developed postoperative complications were both significantly
lower than those for patients who did not develop any complications. In contrast, in the CXCR2-negative group,
there was no significant difference in long-term prognosis between patients with and without complications.
CXCR2 positivity combined with postoperative complications was an independent risk factor for subsequent tumor
recurrence, showing the highest hazard ratio.
Conclusions: Our results suggest that the patients with CXCR2-positive esophageal cancer who develop
postoperative complications have a poor prognosis and should be carefully followed.
Trial registration: This study was approved by Keio University School of Medicine Ethics Committee with a trial
registration number of 2011-241.
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Esophageal cancer is the eighth most common cancer
worldwide, with an estimated 482,000 new cases (3.8 %
of the total) diagnosed in 2008, and the sixth most com-
mon cause of cancer-related death, with 407,000 deaths
(5.4 % of the total) in 2008 [1]. The prognosis of esopha-
geal cancer is generally poor because of its biological ag-
gressiveness and anatomical characteristics. According
to the American Joint Committee on Cancer (AJCC),
the postoperative 5-year survival rate is approximately
90 % for stage I esophageal cancer, and it decreases to
45 % for stage II, 20 % for stage III, and only 10 % for
stage IV [2].
Esophagectomy with radical lymphadenectomy repre-
sents the standard treatment for patients with clinically
resectable esophageal cancer [3]. Recently, it was re-
ported that preoperative chemotherapy or preoperative
chemoradiotherapy followed by surgery improves prog-
nosis compared with surgery alone [4]; however, the
overall survival (OS) rate remains unsatisfactory. There-
fore, there remains an urgent need to identify novel
promising markers that can be used to predict the sur-
vival outcome as well as a new groundbreaking therapy
for esophageal cancer.
Radical esophagectomy is one of the most invasive sur-
gical treatments for digestive tract cancer, and the blood
levels of inflammatory cytokines such as interleukin
(IL)-1, IL-6, and IL-8 are increased for several hours
after surgery. In addition, compared with other surgeries,
esophagectomy is associated with a higher rate of com-
plications, such as postoperative pneumonia and anasto-
motic leakage [5, 6]. Such postoperative complications
are known to cause a cytokine storm [7].
Chemokines are small chemotactic cytokines that me-
diate communication among different cell types [8].
CXCR2, an IL-8 receptor, is a member of the G-
protein–coupled receptor superfamily and the receptor
of Glu–Leu–Arg (ELRþ) CXC chemokines. CXCL1,
CXCL2, CXCL3, CXCL5, and CXCL7 bind specifically
to CXCR2, while CXCL6 and CXCL8 (IL-8) are shared
ligands of CXCR1 and CXCR2 [9]. CXCR2 expression
has been demonstrated in neutrophils, monocytes, eo-
sinophils, mast cells, basophils, lymphocytes, epithelial
cells, and endothelial cells. In addition, CXCR2 is
expressed on several carcinomas, and IL-8 signaling pro-
motes proliferation, survival, and invasion of cancer cells
as well as angiogenesis within tumors [9–12]. Previously,
we reported that the expression of both IL-8 and
CXCR2 in esophageal squamous cell carcinoma (ESCC)
was an independent predictor of prognosis [13].
Some reports on a variety of malignancies demon-
strated that postoperative complications may have either
a positive or negative impact on long-term oncological
survival [14–18]. The same thing goes for esophagealcancer. Some studies have shown that postoperative
complications are negative predictors of the long-term
survival after esophagectomy [19–21]. However, other
studies reported that postoperative complications are
not associated with long-term survival after esophagec-
tomy [22–24].
It has been reported that serum and plasma levels of
IL-8 are enhanced in patients with sepsis, acute lung in-
jury (ALI), and pneumonia [25–27].
In our present study, we hypothesized that CXCR2 ex-
pression could stratify prognosis in ESCC patients with
postoperative complications. To clarify the prognostic
significance of CXCR2 expression and its relationship
with common clinicopathological factors, particularly
postoperative complications, in ESCC, we retrospectively




Eighty-two patients who underwent transthoracic esoph-
agectomy for ESCC at Keio University Hospital (Tokyo,
Japan) between 1997 and August 2002 were examined.
Patients were included in the study if they meet the fol-
lowing criteria: (1) histologically proven squamous cell
carcinoma of the thoracic esophagus, (2) no microscopic
residual tumor (R0), (3) no past history of neoadjuvant
chemotherapy or chemoradiotherapy for ESCC, (4) no
other cancer, and (5) no steroid use during the peri-
operative period. Informed consent was obtained from
each patient enrolled in this study. All patients under-
went two- or three-field lymph node dissection through
right thoracotomy, either video-assisted thoracic surgery
or open thoracotomy [2, 28]. Physical examinations
before surgery did not detect high-risk factors for
transthoracic esophagectomy under general anesthesia
in any of the patients. Informed consent was obtained
from each patient enrolled in this study. The study
was approved by Keio University School of Medicine
Ethics Committee.
Morbidity following esophagectomy
The incidence of postoperative complications was de-
termined by inspection of patients’ medical records.
Vocal cord palsy was defined as hoarseness at the
time of discharge. Pneumonia was defined as an ab-
normal shadow on a chest radiograph with fever
(>38 °C), positive sputum, and/or a white blood cell
count of ≥12,000/mm3. Postoperative complications
were defined as complications of a grade equal to or
higher than grade II according to the Clavien–Dindo
classification [29]: grade I, any deviation from the
normal postoperative course without the need for
pharmacologic treatment or surgical, endoscopic, or
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logic treatment with drugs; grade III, requiring surgi-
cal, endoscopic, or radiologic intervention; grade IV,
life-threatening complication requiring intensive care
unit management; and grade V, death.
Follow-up
All patients were surveyed after esophagectomy in
order to detect recurrences. Physical examinations
and serum CEA and squamous cell carcinoma antigen
tests were performed every 3 months. CT scans from
the neck to the upper abdomen and upper gastro-
intestinal endoscopy were performed from every
6 months.
Tumor recurrence was classified as locoregional or
distant. Locoregional recurrence was defined as re-
currence at the primary site including the anasto-
mosis and regional lymph nodes. It was described as
distant recurrence when located in the liver, lungs, or
other distant organs. OS was measured from the date
of surgery to the date of death, or last follow-up.
Recurrence-free survival (RFS) was measured from
the date of surgery to the date of first evidence of re-
lapse. For patients who had not relapsed or died, RFS
was censored at the last date at which the absence of
relapse was confirmed.Table 1 Associations between CXCR2 expression and clinical backgr
Factors All patients CXC
(n = 82) (n =
Age (years)
≦49 3 (3.7 %) 1 (3
50–59 40 (48.8 %) 17 (
60–69 31 (37.8 %) 13 (
≧70 8 (9.8 %) 2 (6
Sex
Male 73 (89.0 %) 28 (
Female 9 (11.0 %) 5 (1
Location
Upper 7 (8.5 %) 2 (6
Middle 52 (63.4 %) 20 (
Lower 23 (28.0 %) 11 (
Approach
Thoracotomy 61 (74.4 %) 25 (
Thoracoscopy 21 (25.6 %) 8 (2
Adjuvant therapy
None 71 (86.6 %) 27 (
Chemotherapy 9 (11.0 %) 5 (1
Chemoradiotherapy 2 (2.4 %) 1 (3Resected specimens and immunohistochemistry
For this study, tissue samples were obtained from esopha-
geal specimens following surgical resection. For immuno-
histochemistry (IHC) analyses, slides were deparaffinized
with xylene and rehydrated in a graded ethanol series
staining. Antigen retrieval was performed using an en-
zyme solution (Proteinase K DAKO®, Glostrup, Denmark).
Endogenous peroxidase activity was quenched with 0.5 %
periodic acid for 10 min at room temperature. CXCR2
rabbit anti-human polyclonal antibodyLS-A803 (diluted at
1:250, LifeSpan BioSciences®, Seattle, WA, USA) was used
as a primary antibody. Prepared sections were incubated
overnight at 4 °C. Slides were subsequently incubated with
labeled secondary antibody for 30 min at room
temperature. We used biotinylated goat anti-rabbit IgG
antibody BA-1000 (Vector®, CA, USA) as the secondary
antibody. Peroxidase activity was detected with the en-
zyme substrate 3,3-diaminobenzidine tetrachloride solu-
tion. On the final section, the slide was lightly
counterstained with hematoxylin and mounted. For each
test case, a negative control was also included, which re-
ceived the same treatment as the test slide, except that the
primary antibody was omitted. We also used esophageal
squamous epithelial cells without inflammation that
lacked CXCR2 expression as negative controls. Positive
controls (neutrophils and monocytes in the spleen foround factors
R2-positive CXCR2-negative p value
33) (n = 49)
0.81
.0 %) 2 (4.1 %)
51.5 %) 23 (46.9 %)
39.4 %) 18 (36.7 %)
.1 %) 6 (12.2 %)
0.33
84.8 %) 45 (91.8 %)
5.2 %) 4 (8.2 %)
0.60
.1 %) 5 (10.2 %)
60.6 %) 32 (65.3 %)
33.3 %) 12 (24.5 %)
0.82
75.8 %) 36 (73.5 %)
4.2 %) 13 (26.5 %)
0.58
81.8 %) 44 (89.8 %)
5.2 %) 4 (8.2 %)
.0 %) 1 (2.0 %)
Table 2 Associations between CXCR2 expression and pathological background factors
All patients CXCR2-positive CXCR2-negative p value
(n = 82) (n = 33) (n = 49)
pT factor 1 40 (48.8 %) 12 (36.4 %) 28 (57.1 %) 0.06
2 10 (12.2 %) 7 (21.2 %) 3 (6.1 %)
3 32 (39.0 %) 14 (42.4 %) 18 (36.7 %)
pN factor 0 31 (37.8 %) 12 (36.4 %) 19 (38.8 %) 0.83
1 51 (62.2 %) 21 (63.6 %) 30 (61.2 %)
Histological stage I 24 (29.3 %) 9 (27.3 %) 15 (30.6 %) 0.95
IIA 7 (8.5 %) 3 (9.1 %) 4 (8.2 %)
IIB 24 (29.3 %) 9 (27.3 %) 15 (30.6 %)
III 27 (32.9 %) 12 (36.4 %) 15 (30.6 %)
Histological type Well 17 (20.7 %) 7 (21.2 %) 10 (20.4 %) 0.65
Moderately 57 (69.5 %) 24 (72.7 %) 33 (67.3 %)
Poorly 8 (9.8 %) 2 (6.1 %) 6 (12.2 %)
Infiltrative growth pattern INF-a 6 (7.3 %) 3 (9.1 %) 3 (6.1 %) 0.86
INF-b 69 (84.1 %) 27 (81.8 %) 42 (85.7 %)
INF-c 7 (8.5 %) 3 (9.1 %) 4 (8.2 %)
Lymphatic invasion (+) 65 (79.3 %) 27 (81.8 %) 38 (77.6 %) 0.64
(−) 17 (20.7 %) 6 (18.2 %) 11 (22.4 %)
Venous invasion (+) 39 (47.6 %) 18 (54.5 %) 21 (42.9 %) 0.30
(−) 43 (52.4 %) 15 (45.5 %) 28 (57.1 %)
INF-a, expansive growth of tumor nests with a well-demarcated border from surrounding tissue; INF-b, intermediate growth pattern, between INF-a and c; INF-c,
infiltrative growth of tumor nests with an ill-defined border from surrounding tissue
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obtained to optimize the conditions. We evaluated
CXCR2 expression in viable ESCC cells on slides that
contained the most invasive tumor lesion. CXCR2 expres-






Fig. 1 Immunohistochemistry of CXCR2. a, b Esophageal cancer cells are n
on the surface and in the cytoplasm of esophageal cancer cells. Scale bars,with no knowledge of the clinicopathological factors.
Cases were considered as CXCR2-positive if more than
10 % of cancer cells exhibited cell wall staining.
We previously confirmed that CXCR2 protein is over-




egative for CXCR2 expression. c, d CXCR2-positive staining is observed
200 and 50 μm
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in TE4 using reverse transcriptase polymerase chain re-
action [13].
Statistical analysis
All data are presented as medians. Statistical signifi-
cance was determined by a non-parametric Mann–
Whitney U test or Fisher’s exact test. Cumulative sur-
vival rates for patient groups were calculated using
the Kaplan–Meier method and were compared using the
Mantel–Cox log-rank test. Cox proportional hazardTable 3 Frequency of postoperative complications
Complications All patients CXC
(n = 82) (n =
Bleeding 1 (1.2 %) 0 (0
Grade IV 1 (1.2 %) 0 (0
Recurrent nerve palsy 5 (6.1 %) 4 (1
Grade II 4 (4.9 %) 3 (9
Grade III 1 (1.2 %) 1 (3
Anastomotic leakage 14 (17.1 %) 5 (1
Grade II 5 (6.1 %) 2 (6
Grade III 9 (11.0 %) 3 (3
Pneumonia 13 (15.9 %) 2 (6
Grade II 9 (11.0 %) 1 (3
Grade III 3 (3.7 %) 1 (3
Grade IV 1 (1.2 %) 0 (0
Pyothorax 5 (6.1 %) 2 (6
Grade II 3 (3.7 %) 0 (0
Grade III 2 (2.4 %) 2 (6
Intestinal obstruction 2 (2.4 %) 1 (3
Grade II 1 (1.2 %) 1 (3
Grade III 1 (1.2 %) 0 (0
Bacteremia 1 (1.2 %) 1 (3
Grade IV 1 (1.2 %) 1 (3
Catheter infection 3 (3.7 %) 3 (9
Grade II 2 (2.4 %) 2 (6
Grade IV 1 (1.2 %) 1 (3
Anastomotic stenosis 1 (1.2 %) 1 (3
Grade III 1 (1.2 %) 1 (3
Glottic edema 2 (2.4 %) 2 (6
Grade III 2 (2.4 %) 2 (6
Intraabdominal abscess 1 (1.2 %) 1 (3
Grade III 1 (1.2 %) 1 (3
Thrombosis 1 (1.2 %) 1 (3
Grade II 1 (1.2 %) 1 (3
Any complication 40 (48.8 %) 17models were used for multivariate analysis of variables for
predicting postoperative survival. A p value of <0.05 was
considered statistically significant. Statistical analyses were




The median age of patients was 59 years (range, 44–
81 years) with a male/female ratio of 73/9 (Table 1). The
pathologic stage, as determined using the sixth editionR2-positive CXCR2-negative p value
33) (n = 49)
.0 %) 1 (2.0 %) >0.99
.0 %) 1 (2.0 %)
2.1 %) 1 (2.0 %) 0.15
.1 %) 1 (2.0 %)
.0 %) 0 (0.0 %)
5.2 %) 9 (18.3 %) 0.70
.1 %) 3 (6.1 %)
.0 %) 6 (12.2 %)
.1 %) 11 (22.4 %) 0.06
.0 %) 8 (16.3 %)
.0 %) 2 (4.1 %)
.0 %) 1 (2.0 %)
.1 %) 3 (6.1 %) >0.99
.0 %) 3 (6.1 %)
.1 %) 0 (0.0 %)
.0 %) 1 (2.0 %) >0.99
.0 %) 0 (0.0 %)
.0 %) 1 (2.0 %)
.0 %) 0 (0.0 %) 0.40
.0 %) 0 (0.0 %)
.1 %) 0 (0.0 %) 0.06
.1 %) 0 (0.0 %)
.0 %) 0 (0.0 %)
.0 %) 0 (0.0 %) 0.40
.0 %) 0 (0.0 %)
.1 %) 0 (0.0 %) 0.16
.1 %) 0 (0.0 %)
.0 %) 0 (0.0 %) 0.40
.0 %) 0 (0.0 %)
.0 %) 0 (0.0 %) 0.40
.0 %) 0 (0.0 %)
(51.5 %) 23 (46.9 %) 0.68
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tients, IIA in 7 (8.5 %) patients, IIB in 24 (29.3 %) pa-
tients, and III in 27 (32.9 %) patients (Table 2).
According to the results of IHC, CXCR2 expression was
observed mainly in the cell wall of the cancer cells (Fig. 1),
and 33 of the 82 cases (40.2 %) were evaluated as CXCR2-
positive.
The patients were divided into two groups: a
CXCR2-positive group and a CXCR2-negative group
(Tables 1 and 2). There were no significant differ-
ences in clinicopathological background factors be-
tween the two groups according to the results of χ2
analysis. Of the 82 patients, 40 (48.8 %) developed
postoperative complications (Table 3). As shown in
Table 3, there were no significant differences in the
rate of complications between the CXCR2-positive
group and the CXCR2-negative group.
Patient survival
The ESCC recurrence rate was 54.5 % (18/33 patients)
in the CXCR2-positive group and 38.8 % (19/49 patients)
in the CXCR2-negative group. Figure 2 shows the
Kaplan–Meier curve for RFS and OS for these two
groups. RFS of patients with CXCR2-positive tumors
tended to be poorer than that of patients with CXCR2-
negative tumors (p = 0.076; Fig. 2a). There was no sig-
nificant difference in OS between the two groups
(Fig. 2b).
In the CXCR2-positive group, the RFS and OS
rates of patients who developed postoperative com-
plications were both significantly lower than those
for patients who did not develop any complications
(p = 0.019, Fig. 3a; p = 0.024, Fig. 3b). In contrast, in
the CXCR2-negative group, there was no significant
difference in RFS and OS between patients with and
without complications (Fig. 3a, b, respectively).
Among patients who developed complications, RFS
was significantly poorer in those with CXCR2-


























Fig. 2 a Recurrence-free survival and b overall survival after esophagectomtumors (p = 0.014; Fig. 3a). With regard to OS, the
same tendency was observed (p = 0.051; Fig. 3b).
Meanwhile, among patients who did not develop compli-
cations, there were no significant differences in RFS and
OS between patients with CXCR2-positive tumors and
those with CXCR2-negative tumors (Fig. 3a, b).
Therefore, we divided these 82 patients into two
groups: those with CXCR2-positive tumors who
developed postoperative complication(s) [CXCR2(+)/
complication(+) group; n = 17 (20.7 %)] and all other
patients [n = 65 (79.3 %)]. RFS for the CXCR2(+)/
complication(+) group was significantly poorer than
that for the other group (p = 0.0009; Fig. 4a). The
same result was obtained for OS (p = 0.0019; Fig. 4b).
Univariate and multivariate analyses were per-
formed to determine the predictors of subsequent
tumor recurrence. We evaluated eight variables for
survival prognosis by univariate analysis (Table 4). A
depth of tumor invasion of pT2 or greater, lymph
node metastasis, a disease stage of pStage IIA or
greater, lymphatic invasion, venous invasion, and
CXCR2(+)/complication(+) status were identified as
predictive markers of RFS. We then performed multi-
variate analysis using Cox’s proportional hazard model
for these six factors. The CXCR2(+)/complication(+)
status was an independent risk factor for subsequent
tumor recurrence, showing the highest hazard ratio
compared with the other preoperative variables and
each pathologic feature.
Recurrence pattern
Patients who relapsed with CXCR2-positive tumors had
a significantly higher incidence of distant metastases
(p = 0.0052; Table 5). Meanwhile, locoregional recurrence
was not significantly correlated with CXCR2 expression.
Discussion
The impact of postoperative complications following
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Fig. 3 a Recurrence-free survival and b overall survival after esophagectomy among the four groups according to CXCR2 expression and
postoperative complications
Nishi et al. World Journal of Surgical Oncology  (2015) 13:232 Page 7 of 9controversial. Some studies report that patients with
postoperative complications have a poor prognosis com-
pared to patients with no complications after esophagec-
tomy [19–21]. Meanwhile, other studies reported that
postoperative complication is not associated with long-
term survival after esophagectomy [22–24].
Many cancers have a complex chemokine network that
influences tumor cell growth, survival, and migration as
well as metastasis and angiogenesis [8]. These findings
are consistent with the hypothesis that the systemic in-
flammatory response plays a significant role in stimulat-
ing tumor growth.
IL-8, one of the proinflammatory chemokines, is
produced by macrophages and other cell types, includ-
ing epithelial cells and endothelial cells. IL-8 is one of
the major mediators of the inflammatory response. Its
primary function is the induction of chemotaxis in its
target cells, e.g., neutrophil granulocytes. IL-8 serves
as a chemical signal that attracts neutrophils to the
site of inflammation; therefore, it is also known as a


























Fig. 4 a Recurrence-free survival and b overall survival after esophagectomIt has been reported that serum and plasma levels of IL-8
are enhanced in patients with sepsis, ALI, and pneumonia
[25–27]. Several studies also reported that serum IL-8 levels
increase after an invasive procedure such as thoracoabdom-
inal esophagectomy [31].
In the present study, we found that 40.2 % of ESCC
specimens stained positively for CXCR2 expression in
IHC, similar to the finding in our previous report [13].
Our results indicated that patients with CXCR2-positive
tumors who developed postoperative complications were
predicted to be at the greatest risk of subsequent tumor
recurrence. In the present study, ESCC patients with
CXCR2-positive tumors who developed postoperative
complications had a significantly poorer RFS compared
with other patients. Multivariate analysis demonstrated
that the combination of CXCR2 expression and postoper-
ative complications was an independent predictor of RFS.
To the best of our knowledge, this is the first report to
demonstrate that the combination of CXCR2 expression
and postoperative complications affects long-term survival


























y between the CXCR2(+)/complication(+) group and the others
Table 4 Multivariate analysis of variables predicting recurrence-free survival with Cox’s proportional hazard model
Factors Univariate p value Multivariate
Hazard ratio (95 % CI) p value
pT (pT1 or ≥pT2) 0.050 1.09 (0.44–2.69) 0.859
pN (pN0 or pN1) 0.015 1.04 (0.28–3.83) 0.952
pStage (pStageI vs other) 0.021 1.62 (0.29–8.93) 0.580
Lymphatic invasion (+) or (−) 0.025 1.27 (0.32–4.98) 0.740
Venous invasion (+) or (−) 0.009 1.62 (0.74–3.55) 0.230
Histological type (poor or others) 0.770
Infiltrative growth pattern (INF-c or other) 0.067
CXCR2(+)/complication(+) or other 0.001 2.51 (1.18–5.35) 0.017
CI confidence interval
Nishi et al. World Journal of Surgical Oncology  (2015) 13:232 Page 8 of 9The current study indicates that there is no relation-
ship between CXCR2 expression and pathological back-
ground such as the depth of tumor invasion, lymph
node metastasis, histological stages, lymphatic invasion,
venous invasion, and histological type. Moreover, for pa-
tients who did not develop complications, there were no
significant differences in RFS and OS between the
CXCR2-positive group and CXCR2-negative group.
These results suggest that CXCR2 expression alone is
not a risk factor for ESCC prognosis and that CXCR2
expression accompanied by IL-8 exposure is a marker of
poor prognosis.
Our study also demonstrated that CXCR2 expression in
esophageal cancer was significantly correlated with the site
of recurrence. Patients with CXCR2-positive tumors
showed a significant tendency to develop distant metasta-
ses, and this result is consistent with that of several studies
reporting that an IL-8 and CXCR2 network promotes
tumor invasion, migration, and metastasis.
The present study has several limitations. First, be-
cause serum IL-8 levels in study patients were not mea-
sured, it remains unclear whether serum IL-8 levels in
patients who developed postoperative complications
were elevated. Second, the current study is a retrospect-
ive study; therefore, there were various sources of bias.
A prospective study including the measurement of
serum IL-8 levels is required in the future.Table 5 Relation between CXCR2 expression and sites of recurrence
CXCR2-positive
(n = 33)
Relapsing patients 19 (57.6 %)
Locoregional recurrence (+) 13 (39.4 %)
Locoregional recurrence (−) 6 (18.2 %)
Distant recurrence (+) 14 (42.4 %)
Distant recurrence (−) 5 (15.2 %)However, it is clear that the combination of CXCR2
expression and postoperative complications is the stron-
gest risk factor for a poor prognosis in ESCC patients.
Therefore, avoidance of postoperative complications and
strict perioperative care are important for patients with
CXCR2-positive tumors. Less toxic neoadjuvant treat-
ments which cause less postoperative complications
might be recommended in the case with CXCR2-
positive tumors proven by preoperative biopsies. Fur-
thermore, if a patient with CXCR2-positive tumors de-
velops complications, a strict follow-up schedule should
be followed and additional postoperative chemotherapy
may be necessary.
Unfortunately, it is not clear whether the most ap-
propriate treatment could be chosen by CXCR2 ex-
pression in this study. Further studies will be needed
on how to choose the appropriate treatments for pa-
tients with CXCR2-positive tumors.
We previously reported that perioperative steroids
reduce the inflammatory cytokines including IL-8 in
an animal model [32]. Furthermore, several clinical
studies have found that preoperative steroid adminis-
tration reduces the production of inflammatory medi-
ators [33, 34]. Administration of a steroid during the
perioperative period and a CXCR2 antagonist may be
effective for inhibiting inflammatory mediators in pa-
tients with CXCR2-positive tumors.CXCR2-negative Total p
value(n = 49) (n = 82)
18 (36.7 %) 37 (45.1 %) 0.063
16 (32.7 %) 29 (35.4 %) 0.130
2 (4.1 %) 8 (9.8 %)
5 (10.2 %) 19 (23.2 %) 0.005
13 (26.5 %) 18 (22.0 %)
Nishi et al. World Journal of Surgical Oncology  (2015) 13:232 Page 9 of 9Conclusions
In conclusion, we demonstrated that the patients with
CXCR2-positive esophageal cancer who develop postop-
erative complications have a poor prognosis and should
be carefully followed.
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